logo-loader
RNS
viewReNeuron Group PLC

Total Voting Rights

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .bc{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 72.0pt 90.0pt;}div.bc{}h1.cb{text-indent:117.0pt}span.cc{font-weight:normal}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}table.ce{margin-left:-5.4pt;border-collapse:collapse}td.bz{width:210.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.ca{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.bw{width:9.0cm;padding:0cm 5.4pt 0cm 5.4pt}h3.bx{text-align: right} span.by{font-size:11.0pt; font-family:"Calibri","sans-serif"}h2.bu{text-align: center}p.cf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.ch{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:1.45pt;text-align:justify}span.ci{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.bq{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}span.bp{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}table.ck{width:411.1pt} tr.bi{height:17.0pt}td.bl{padding:0cm 0cm 0cm 0cm;height:17.0pt}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold}span.bn{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}td.bj{width:25.5%;padding:0cm 0cm 0cm 0cm; height:17.0pt}span.bk{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.cm{font-family:"Calibri","sans-serif";color:black;font-size:11.0pt}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;background:white}span.bf{font-family:"Calibri","sans-serif"}span.bd{font-size:11.0pt; font-family:"Calibri","sans-serif";color:red} /**/
RNS Number : 5838H
ReNeuron Group plc
01 August 2019
 

 

 

1 August 2019

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Total Voting Rights

 

At 31 July 2019, the Company had 31,832,270 ordinary shares in issue, each carrying one voting right. This follows the issue of 27,653 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.

 

As the Company holds no ordinary shares in treasury, the figure of 31,832,270 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

  

ENDS

 

ENQUIRIES:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer

 

 


Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 

 


Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison

(NOMAD and Joint Broker)

 

 


N+1 Singer

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Iqra Amin (Joint Broker)


 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRDMGGRGMNGLZM

Quick facts: ReNeuron Group PLC

Price: 126

Market: LSE
Market Cap: £40.11 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18